

February 4, 2020

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001
Scrip Code: 524558

To
The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai - 400 001
Scrip Code: NEULANLAB; Series: EQ

Dear Sirs,

Sub: Intimation under Regulation 29 & 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We refer to our letter dated January 16, 2020, intimating that a meeting of the Board of Directors of the Company would be held on Tuesday, February 11, 2020, inter alia, to consider the Unaudited Financial Results of the Company for the quarter ended December 31, 2019.

Further to the aforementioned letter, we would like to inform that the Board of Directors, at the Board Meeting scheduled on February 11, 2020, would, inter alia, also consider the recommendation of interim dividend for the financial year 2019-20, if any, along with the Unaudited Financial Results for the quarter ended December 31, 2019.

Pursuant to Regulation 42 of the SEBI (LODR) Regulations, 2015, we also inform you that subject to afore-mentioned recommendation by the Board of Directors, **Friday, February 14, 2020**, shall be the **Record Date** for the purpose of payment of interim dividend.

In continuation, to our letter dated December 31, 2019, as per the provisions of the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information of the Company, the trading window for dealing in the securities of the Company which was closed from January 1, 2020 shall open after forty-eight hours of declaration of Unaudited Financial Results of the Company for the quarter ended December 31, 2019 and recommendation of interim dividend, if any, to the Stock Exchanges.

This is for your information and records.

Thanking you,

Yours faithfully,
for Neuland Laboratories Limited



Sarada Bhamidipati
Company Secretary

